“You have to be on your game continually, you have to continually self-evaluate, and the field moves quickly.”
ONCOLOGY Vol 36, Issue 12
Bradford S. Hoppe, MD, MPH, and Omran Saifi, MD, offer a peer perspective on research by Gavin Jones, MD, and colleagues into radiation therapy in diffuse large B-cell lymphoma.
Co-editor-in-Chief Howard S. Hochster, MD, reviews the major clinical and scientific developments of 2022 in the oncology space.
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data
ByAlberto Calvo-García, PharmG,María Pérez Abánades, PharmG,Silvia Ruíz-García, PharmG,Ana Beatriz Fernández Román, PharmG,Javier Letellez Fernández, PharmG,Beatriz Candel García, PharmG,Carlos Hernández Terciado, PharmG,Raquel De Santiago Álvarez, PharmG,Rebeca Mondéjar Solis, MD,Berta Hernández Marin, MD,Patricia Toquero Diez, MD,Alberto Morell Baladrón, PharmG,Ramón Colomer Bosch, MD
Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Gavin Jones, MD, and colleagues explore the landscape of radiation therapy in diffuse large B-cell lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
3
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
4
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
5
